Comparative Pharmacology
Head-to-head clinical analysis: MAXIDEX versus TRIACET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXIDEX versus TRIACET.
MAXIDEX vs TRIACET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAXIDEX (dexamethasone) is a potent glucocorticoid that binds to the glucocorticoid receptor (GR), leading to modulation of gene expression and inhibition of inflammatory mediators such as prostaglandins and leukotrienes. It suppresses immune response through inhibition of cytokine production (e.g., IL-1, IL-2, TNF-alpha) and reduces vasodilation and vascular permeability.
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
One to two drops of the 0.1% ophthalmic suspension into the conjunctival sac every hour during the day and every two hours at night initially; after improvement, reduce to one drop every four hours, then one drop three to four times daily.
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for dexamethasone; in ocular tissues, half-life may be prolonged due to local retention, but systemic half-life is short with minimal accumulation.
Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment.
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for <15% unchanged drug; biliary/fecal elimination of metabolites predominates.
Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination.
Category C
Category C
Corticosteroid
Corticosteroid